Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

1. Males or female subjects 6 to 17 years of age, inclusive, at the time the informedconsent form is signed by the legal guardian

2. Subjects must have a weight of ≥ 20 kg

3. Diagnosis of chronic plaque psoriasis for at least 6 months prior to Screening.

4. Has moderate to severe plaque psoriasis at Screening and Baseline as defined by:

• PASI score ≥ 12; and

• Body surface area (BSA) ≥ 10%; and

• sPGA ≥ 3 (moderate to severe)

5. Disease inadequately controlled by or inappropriate for topical therapy forpsoriasis

6. Candidate for systemic therapy or phototherapy

Exclusion Criteria:

1. Guttate, erythrodermic, or pustular psoriasis at Screening and Baseline

2. Psoriasis flare or rebound within 4 weeks prior to Screening

3. Prior history of suicide attempt at any time in the subject's lifetime prior toScreening or randomization in the study, or major psychiatric illness requiringhospitalization within 3 years prior to signing the assent and informed consent

4. Answer "Yes" to any question on the Columbia-Suicide Severity Rating Scale duringScreening or at Baseline

5. Current or planned concurrent use of the following therapies that may have apossible effect on psoriasis a. Topical therapy within 2 weeks prior to randomization (including but not limitedto topical corticosteroids, topical retinoid or vitamin D analog preparations,tacrolimus, pimecrolimus, or anthralin/dithranol) Exceptions*: i. Low potency or weak corticosteroids (please refer to the Investigators' Manual)will be allowed as background therapy for treatment of the face, axillae and groinin accordance with manufacturer's suggested usage ii. Unmedicated skin moisturizer (eg, Eucerin®) will also be permitted for body lesions

*Subjects should not use these topical treatments within 24 hours prior to theclinic visit. b. Conventional systemic therapy for psoriasis within 4 weeks prior to randomizationc. Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 4 weeks prior torandomization d. Biologic therapy within 4 weeks prior to randomization or 5 PK/PDhalf-lives (whichever is longer).